Equity
€224,050 ▲ 21.6%
AmbEryn paid out €50,000 in dividends. That is 56% of the 2025 profit.
AmbEryn
Lifetime
4 annual accounts with figures on one time axispeak €122,554 (2025)
€122,554▲ 16.4%
peak €89,795 (2025)
€89,795▲ 20.5%
peak €224,050 (2025)
€224,050▲ 21.6%
€42,450▲ 230%
peak 0 FTE (2025)
0 FTE
Board2 names since 2021
2 directors and 1 other
Documentsfilings and deeds
23-07-20268 days before the deadline
2025abbreviated format
Gross margin from €105,269 to €122,554Dividend €50,000Equity from €184,255 to €224,050Debts from €12,847 to €42,450Investments €61,194Cash from €35,943 to €120,668
Key points
from the 2025 annual accountsTurnover
≈ €230,000 estimated
The accounts state no turnover.
Investments
€61,194 6.9 × depreciation
Green is investment, beige is depreciation. Machinery stands 51.7% higher than in 2024.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,969 companies had the same profile as AmbEryn has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.4%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,969 companies, not a prediction for AmbEryn. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 22-07-2021
Manager, since 01-04-2022
- 1,000 sharesdeed of 28-07-2021
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0771725169
Appointment: (manager)
General meeting of 30-03-2022 · Gazette deed
Incorporation
Founding capital of €3,000, 1,000 shares · Founder: · Appointment: (director) · published on 28-07-2021 · Gazette deed
First establishment
Nijvelsebaan 204, Bertem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| AmbEryn Bertem | €266,500 | €122,554 | 84.1% | 0 |
| Dokter Liesbet De Wachter Leuven | €296,602 | €106,245 | 22.0% | 0 |
| Dr. Katherine Vandenborre Herent | €262,545 | €107,443 | 78.7% | 0 |
| Dr. Thomas Verdonck Antwerp | €241,536 | €93,660 | 91.8% | 0 |
| MEDRG Esneux | €245,147 | €140,157 | 8.5% | 0.1 |
| DR. MARTA MALINOWSKA, CHIRURG Wezembeek-Oppem | €147,237 | €107,253 | 3.4% | 0 |
| Dr. Charlotte Fierens Boutersem | €170,048 | €117,375 | 80.8% | 0 |
These companies have the same main activity as AmbEryn: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €147,000 and €297,000, founded between 2017 and 2023.
Official details
Source: KBO- Status
- Active since 26-07-2021Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.320.490.6163060 Bertem, since 26-07-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 21-10-2026
Annual accounts 2025
- €266,500▲ 35.2%
- Filing
- Filed on 23-07-2026, 8 days before the end of the filing period
Insights on AmbEryn
AmbEryn files the abbreviated format. That format states no turnover. The gross margin rose from €75,872 in 2022 to €122,554 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about AmbEryn
- What is the company number of AmbEryn?
- The company number of AmbEryn is 0771.725.169. The VAT number is the same number with BE in front: BE 0771.725.169.
- Where is AmbEryn based?
- The registered office is at Nijvelsebaan 204, 3060 Bertem.Company details
- What does AmbEryn do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of AmbEryn?
- AmbEryn is a private limited company (BV).
- When was AmbEryn founded?
- AmbEryn was founded on 26-07-2021.
- Is AmbEryn still active?
- Yes, AmbEryn is an active enterprise in the KBO register.
- What is the turnover of AmbEryn?
- The turnover in financial year 2025 is ≈ €230,000. This figure is estimated from the gross margin of €122,554 and 41 comparable companies (NACE 86220). It probably lies between €190,000 and €300,000.Financials
- Is AmbEryn profitable?
- In financial year 2025, AmbEryn made a profit of €89,795.
- Where can I find the annual accounts of AmbEryn?
- AmbEryn filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of AmbEryn due?
- AmbEryn must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.